- Synonyms: Corlutin; Luteohormone; Pregnenedione; Pregn-4-ene-3,20-dione; Progestin; Progestone
- OSHA IMIS Code Number: P446
- Chemical Abstracts Service (CAS) Registry Number: 57-83-0
- NIOSH Registry of Toxic Effects of Chemical Substances (RTECS) Identification Number: TW0175000
- Chemical Description and Physical Properties:
- white, odorless crystals
- molecular formula: C21H30O2
- molecular weight: 314.47
- melting point: 129-130°C
- Carcinogenic Classification:
- International Agency for Research on Cancer (IARC): Group 2B, Possibly carcinogenic to humans (progestins)
- National Toxicology Program (NTP): Reasonably Anticipated to be Human Carcinogen
- Potential Symptoms: Skin and eye irritation, photosensitivity which can result in dermatologic lesions; changes in mood
- Health Effects: Toxic; may cause heritable genetic damage; may impair fertility; possible risk of harm to the unborn child
- Affected Organs: Reproductive system; central nervous system
- Progesterone is an OSHA Select carcinogen, but no PEL has been established.
- Although progesterone is an endogenous hormone important for the maintenance of a normal pregnancy, it is listed in a NIOSH Alert as one of the drugs that should be handled as a hazardous drug.
- Plasma progesterone levels fall markedly around the time of amenorrhea in peri-menopausal women and remain low in postmenopausal women. Progesterone levels are relatively stable in men 40-80 years of age.
- Progesterone is metabolized into a number of other biologically active steroids including allopregnanolone, as well as into urinary metabolite markers of progesterone status, pregnanediol and pregnanetriol.
- Some CNS effects of progesterone are thought to involve the modulation of GABA(A) receptor activity by the progesterone metabolite allopregnanolone.
- No adverse effects of occupational exposure to progesterone were located in the biomedical literature.
- Literature Basis:
- National Institute for Occupational Safety and Health: NIOSH Alert: Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings. NIOSH Publication No. 2004-165.
- Andréen, L., Sundstrom-Poromaa, I., Bixo, M., Andersson, A., Nyberg, S. and Bäckström, T.: Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology 30(2): 212-224, 2005.
- Bélanger, A., et al.: Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J. Clin. Endocrinol. Metab. 79(4): 1086-1090, 1994.
- Golub, M.S., Kaufman, F.L., Campbell, M.A. Li, L.-H., et al.: Evidence on the developmental and reproductive toxicity of progesterone (draft). Reproductive and Cancer Hazard Assessment Section, Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, (August) 2004, 71 pp.
- No authors listed: Progesterone (CAS No. 57-83-0). Report on Carcinogens (latest edition); U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program, 2005.
- Soderpalm, A.H., Lindsey, S., Purdy, R.H., Hauger, R. and Wit de H.: Administration of progesterone produces mild sedative-like effects in men and women. Psychoneuroendocrinology 29(3): 339-354, 2004.
- Trévoux, R., De Brux, J., Castaner, M., Nahoul, K., Soule, J.-P. and Scholler, R.: Endometrium and plasma hormone profile in the peri-menopause and post-menopause. Maturitas 8(4): 309-326, 1986.
- Date Last Revised: 04/28/2006
Monitoring Methods used by OSHA
Laboratory Sampling/Analytical Method:
- Glass Fiber Filter (37 mm open face) in 3-piece cassette
- maximum volume: 240 Liters
- maximum flow rate: 1.0 L/min
- maximum time: 240 Minutes
- current analytical method: High Performance Liquid Chromatography; HPLC/UV at 240 nm
- analytical solvent: Methanol
- method reference: OSHA Analytical Method (OSHA PV2001)
- method classification: Partially Validated
** All Trademarks are the property of their respective owners.